Carisma Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting
April 9, 2021
PHILADELPHIA — Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of Carisma’s proprietary chimeric antigen receptor macrophage (CAR-M) platform, as well as the importance of evaluating CAR-monocytes (CAR-Mono) as a novel and expedited immunotherapeutic pathway. Please click here for more information.